Nant Urothelial Cancer Vaccine

The **Nant Urothelial Cancer Vaccine** is an investigational cancer immunotherapy developed by ImmunityBio and affiliated Nant companies. It is designed to target urothelial carcinoma and consists of a multi-modal regimen that combines metronomic low-dose chemotherapy, radiation therapy, natural killer (NK) cell-based technology, and antigen-specific vaccines (adenoviral- and yeast-based) to activate the patient’s immune response against cancer cells. The vaccine also incorporates proprietary NK cells and the IL-15 superagonist N-803 (Anktiva), aiming to stimulate robust tumor-specific T-cell activity and immune memory. It is part of a broader program targeting multiple cancers and is currently being clinically studied in urothelial carcinoma as part of the QUILT-3.048 trial and possibly other 'QUILT' protocols[1][2][8].

Brand names

Nant Urothelial Cancer Vaccine

Other names

NANT Cancer VaccineNCV